Neeraj Agarwal: Excellent talk by Heather Cheng at APCCC24
Neeraj Agarwal shared a post on X:
“Excellent talk by Heather Cheng on who should undergo germline testing at Advanced Prostate Cancer Co (APCCC24).
Ongoing neoadjuvant trials in germline mutation, prostate cancer and take home message below.”
The Majority of the panelists obtain germline and somatic tumor testing in pts with mHSPC and mCRPC.
Source: Neeraj Agarwal/X
Neeraj Agarwal is a Professor of Medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program, and the Center of Investigational Therapeutics (CIT) at the HCI. Dr. Agarwal is an Advisor to the Oncology Drug Advisory Committee and the United States Food and Drug Administration, leads early therapeutics in the SWOG genitourinary cancers committee, and is the Chief Editor of ASCO Daily News.
The APC Society, a non-profit organization, aims to improve the treatment and care of men with advanced prostate cancer. It organizes the Advanced Prostate Cancer Consensus Conference (APCCC) and serves as its legal representative in Switzerland.
